Hospitalization | |
Country | Results |
France [20] | 31/36 have been hospitalized once during the study period (1998–2003) |
 | 0.4 admission/patient/month |
 | 46% have been hospitalized during the first 6 months. The percentage decreases to 21% after the first year |
Denmark [22] | 30,358 patients/day (64 asPD patients), 10% of which have been spent in hospital, with a length of stay longer for older (> 70 years) and for asPD compared with self-PD (35 vs 19 hospital days/patient/year) |
 | 1 admission every 3.1 treatments/months |
Brazil [25] | 15/30 patients (50%) have been hospitalized during the first 6Â months, with cardiovascular disease being the most common cause |
Canada, Ontario [16] | 1.4 admissions/patients/year and 23.5 hospital days/patient/year |
Canada, Ontario [18] | 203Â asPDÂ vs 198 in-center HD: 11.1 vs 12.9Â days/year |
Canada, British Columbia [19] | Non-significant differences between 53 asPD 57 PDA eligible* and 670 self-PD after adjusting for comorbidities |
Peritonitis risk | |
France [20] | Survival free of peritonitis was 72% at six months, 50% at 12Â months |
Denmark | Incidence of 1 in every 25.3 patients/months in asPD vs 1 in every 30 patients/months in self-PD patients |
Canada, Ontario [16] | Non-significant differences between asPD and self-PD patients (1 in every 28.2 patients/months in self-PD vs 1 in every 24.9 patients/months) |
Canada, British Columbia [19] | Non-significant differences between 53 asPD 57, PDA eligible* and 670 self-PD in both non-adjusted and adjusted analyses (0.22 vs 0.36 vs 0.22 patients-year) |
Brazil [25] | 1 episode in every 36 patients/months |
Technique survival | |
France [20] | 85% at 6Â months and 58% at 12Â months |
 | 8/36 were transferred to HD |
Denmark [22] | No differences between self- and assisted PD patients |
Canada, Ontario [16] | 81% at 12Â months |
Canada, British Columbia [19] | Not-significant different between asPD, PDA eligible* and self-PD patients (88% vs 86% vs 83% of death- and transplant-censored PD technique survival at 12Â months) |
Patient survival | |
France [20] | Patient survival was 90% at six months and 83%at 1Â year |
Denmark [22] | Patient survival was 75–80% at 1 year |
Canada, Ontario [16] | Death rate 0.12 patients/year |